系统效能视角下基于改进ADC法的研究生导师能力多维度矩阵构建研究

导师作为研究生培养过程中的第一责任人,其能力高低直接影响研究生的培养质量。文章基于“五位一体”理念提出的“导研、导学、导言、导行、导心”,将导师能力细化为个人能力、课堂教学能力、日常学术指导能力、研究生的学术成果和研究生非学术成果五大部分,应用结构分析法(Availability Dependability Capability,ADC)的可用性、可靠性和指导能力的概念,构建相应的研究生导师能力多维度矩阵,综合全面地反映导师的能力,为进一步提高研究生培养质量提供参考。

ADC药物联合免疫治疗在膀胱癌的应用

膀胱癌(bladder cancer,BCa)是一种常见的泌尿系恶性肿瘤,以尿路上皮癌最常见。长期以来,都以化疗为主,尽管有多种治疗方式,但一些患者会出现疾病复发和转移,总体预后不良,长期生存率低。抗体-药物偶联物(antibody-drug conjugates,ADC)结合了抗体药物的靶向能力和化疗药物的细胞毒性,最近已成为个体化精准癌症治疗发展的一个突出研究重点。目前,基于ADC的联合疗法,特别是ADC联合免疫检查点抑制剂(immune checkpoint inhibitors,ICIs),已经显示出可喜的疗效。这种联合方法推进了BCa的治疗,显示出未来成为晚期BCa标准一线治疗的潜力。因此,本文对免疫联合ADC药物治疗BCa作一述评。

基于ADC和AHP的舰载双波段雷达作战效能评估

针对舰载双波段雷达作战效能评估问题,提出一种基于ADC和AHP的作战效能评估方法。首先,建立了适用于舰载双波段雷达特点的ADC模型,给出了各因子的具体评估过程。然后,通过AHP给出了能力因子各指标权重系数的计算方法。最后以某舰载双波段雷达为例,给出了模型的应用实例。该模型可操作性强,能准确评估舰载双波段雷达作战效能。

基于粗细量化并行与TDC混合的CMOS图像传感器列级ADC设计方法

针对传统单斜式模数转换器(Analog-to-Digital Converter,ADC)和串行两步式ADC在面向大面阵CMOS(Complementary Metal Oxide Semiconductor)图像传感器读出过程中的速度瓶颈问题,本文提出了一种用于高速CMOS图像传感器的全并行ADC设计方法.该方法基于时间共享和时间压缩思想,将细量化时间提前到粗量化时间段内,解决了传统方法的时间冗余问题;同时采用插入式时间差值TDC(Time-to-Digital Converter),实现了全局低频时钟下的快速转换机制.本文基于55-nm 1P4M CMOS工艺对所提方法完成了详细电路设计和全面测试验证,在模拟电压3.3 V,数字电压1.2 V,时钟频率250 MHz,输入电压1.2~2.7 V的情况下,将行时间压缩至825 ns,ADC的微分非线性和积分非线性分别为+0.6/-0.6LSB和+1.6/-1.2LSB,信噪失真比(Signal-to-Noise-and-DistortionRatio,SNDR)为68.271 dB,有效位数(Effective Numbers Of Bits,ENOB)达到11.0489 bit,列不一致性低于0.05%.相比现有的先进ADC,本文提出的方法在保证低功耗、高精度的同时,ADC转换速率提高了87.1%以上,为高速高精度CMOS图像传感器的读出与量化提供了一定的理论支撑.

面向高帧率CMOS图像传感器的12位列级全差分SAR/SS ADC设计

针对高帧率CMOS图像传感器的应用需求,提出一种结合逐次逼近型(Successive Approximation Register,SAR)和单斜坡(Single Slope,SS)结构的混合型模拟数字转换器(Analog to Digital Converter,ADC)。该ADC的分辨率为12位,其中SAR ADC实现高6位量化,SS ADC实现低6位量化。该ADC采用了全差分结构消除采样开关的固定失调并减少非线性误差,同时在SAR ADC中采用了异步逻辑电路进一步缩短转换周期。采用110 nm 1P4M CMOS工艺对该电路进行了设计和版图实现,后仿真结果表明,在20 MHz的时钟下,转换周期仅为3.3μs,无杂散动态范围为77.12 dB,信噪失真比为67.38 dB,有效位数为10.90位。

用于GEM-TPC探测器读出芯片的10 bit20 MSPS SAR ADC设计

随着大面积气体电子倍增器——时间投影室探测器的不断发展,其对读出电子学的密度和集成度要求越来越高。基于180 nm的CMOS工艺设计完成了一款10 bit、20 MSPS的逐次逼近寄存器型模数转换器原型芯片。利用该芯片结合模拟前端模块和数字信号处理器,可实现全数字化的前端读出专用集成电路用于GEM-TPC的读出。该ADC主要由DAC模块、动态比较器模块、异步时钟生成模块和SAR逻辑模块构成。仿真结果表明,输入信号频率为1.836 MHz时,ENOB为8.61 bit,内核功耗约为3.3 mW/Ch。

高精度低功耗噪声整形SAR ADC设计

针对传统无源有损积分环路滤波器相较于有源无损积分环路滤波器,具有功耗低、电路设计简单等特点,但其噪声传输函数(NTF:Noise Transfer Function)平滑,噪声整形效果较弱的问题,提出了一种无源无损的二阶积分环路滤波器,保留了无源有损积分优点的同时具有良好噪声整形效果。设计了一款分辨率为16 bit、采样率为2 Ms/s的混合架构噪声整形SAR ADC。仿真结果表明,在125 kHz带宽、过采样比为8时,实现了高信号与噪声失真比(SNDR(Signal to Noise and Distortion Ratio)为91.1 dB)、高精度(14.84 bit)和低功耗(285μW)的性能。

一种具有1~128倍可变增益放大器的低功耗Sigma⁃Delta ADC

为满足传感器应用的低功耗需求,设计并实现了一种低功耗Sigma⁃Delta模数转换器(ADC)芯片。该ADC采用一阶全差分开关电容Sigma⁃Delta调制器,且集成了可编程增益放大器(PGA)和Bandgap;使用1.5 bit量化结构,相较于1 bit量化结构减小了3 dB的量化误差;使用优化的反馈电路,减小了电容失配引入的误差;PGA采用轨到轨的运放电路拓扑,增大了整个芯片的电压适应范围。基于180 nm CMOS工艺对该ADC进行了设计和流片。测试结果表明:该Sigma⁃Delta ADC在采样频率512 kHz、过采样率(OSR)为256时,峰值信噪谐波失真比(SNDR)和有效位数(ENOB)分别为75.29 dB和12.21 bit,芯片功耗仅为0.92 mW。芯片能在2.3~5.5 V宽电源电压范围内正常工作,可实现最大128 V/V的增益。适用于小型传感器的信号测量应用,可以满足小型传感器低功耗、高精度的需求。

稀土Ce变质对ADC12铝合金组织及力学性能的影响

采用光学显微镜、扫描电镜、拉伸试验机及布氏硬度计研究了稀土Ce改性处理对ADC12铝合金微观组织及力学性能的影响。结果表明:当加入质量分数为0.6%的稀土Ce时,组织中粗大的初生α-Al相变得圆整、细小且分布均匀,共晶Si相由针片状变为颗粒状。稀土Ce与合金中的Al元素发生共晶反应生成Al11Ce3等金属间化合物,在扫描电镜下化合物形状为长条针状,并呈亮白色。添加质量分数为0.6%Ce有效提高了合金的屈服强度、抗拉强度和伸长率,分别达到171.72、260.37 MPa和4.1%,与未添加Ce元素的合金相比分别提升了33.83%、48.69%和155%,与此同时,合金的布氏硬度也达到峰值,为88 HB。

应用于高速图像传感器的高线性度Latch ADC

针对高速应用设备对CMOS图像传感器高速、高线性度的要求,本文在传统SS ADC(Single Slope ADC,单斜模数转换器)的基础上,实现了一款应用于图像传感器的Latch ADC,工作频率达到了600 MHz。Latch ADC可以多列像素共用一个Gray Code计数器,并通过Latch结构快速锁定和存储数据,实现了SS ADC中Counter和SRAM的功能。本文采用110 nm工艺,实现了一种高速12位Latch ADC。经过仿真验证,本文的Latch ADC具有高线性度,每次转换的周期为7.094μs,平均功率为180.3μW,转换功耗为1.279 nJ.

一种高精度流水线ADC系统设计与建模方法

针对传统模数转换器(analog to digital convertor,ADC)设计复杂度高、仿真迭代时间长的问题,提出了一种高精度ADC系统设计与建模方法。该方法以10 bit 50 MHz流水线ADC为例,首先选取分离采样架构,进行电路的s域变换理论分析;其次对电路中各种非理想噪声的表达式进行精确推导,根据系统中的运放功耗指标进行参数优化;最后分别在MATLAB和Cadence软件中建立模型,进行100点蒙特卡洛仿真。仿真结果表明,在TSMC 180 nm工艺失配下,该流水线ADC有效位数达到9.70 bit,无杂散动态范围维持在76 dB附近,微分非线性在0.3 LSB以内,积分非线性在0.5 LSB以内,核心功耗在8 mW,该分析方法在保证流水线ADC优异性能的同时,大幅提高了设计效率。

Diagnosis of poorly differentiated adenocarcinoma of the stomach by confocal laser endomicroscopy:A case report

BACKGROUND In recent years,confocal laser endomicroscopy(CLE)has become a new endoscopic imaging technology at the microscopic level,which is extensively performed for real-time in vivo histological examination.CLE can be performed to distinguish benign from malignant lesions.In this study,we diagnosed using CLE an asymptomatic patient with poorly differentiated gastric adenocarcinoma.CASE SUMMARY A 63-year-old woman was diagnosed with gastric mucosal lesions,which may be gastric cancer,in the small curvature of the stomach by gastroscopy.She consented to undergo CLE for morphological observation of the gastric mucosa.Through the combination of CLE diagnosis and postoperative pathology,the intraoperative CLE diagnosis was considered to be reliable.According to our experience,CLE can be performed as the first choice for the diagnosis of gastric cancer.CONCLUSION CLE has several advantages over pathological diagnosis.We believe that CLE has great potential in the diagnosis of benign and malignant gastric lesions.

稀土Ce变质铸造ADC12铝合金的组织及性能

通过添加稀土Ce的方式对ADC12铝合金进行了变质处理,采用显微组织观察、拉伸试验、断口形貌观察等手段研究了0~0.9%Ce对ADC12铝合金组织和力学性能的影响。结果表明:稀土Ce对ADC12铝合金有较好的变质效果。随着Ce添加量的增加,ADC12合金组织中α-Al相面积分数先升高后降低,合金的抗拉强度和伸长率先升高后降低。Ce添加量0.5%的合金中α-Al相面积分数达到最大值40.2%,其抗拉强度和伸长率也达到最大值,分别为258.2 MPa和3.5%,与未变质的ADC12合金相比,分别提高了37.7%和94.4%。

Stereotactic body radiotherapy in pancreatic adenocarcinoma

Background:Stereotactic body radiotherapy(SBRT)in pancreatic cancer allows high delivery of radiation doses on tumors without affecting surrounding tissue.This review aimed at the SBRT application in the treatment of pancreatic cancer.Data sources:We retrieved articles published in MEDLINE/PubMed from January 2017 to December 2022.Keywords used in the search included:“pancreatic adenocarcinoma”OR“pancreatic cancer”AND“stereotactic ablative radiotherapy(SABR)”OR“stereotactic body radiotherapy(SBRT)”OR“chemoradiotherapy(CRT)”.English language articles with information on technical characteristics,doses and fractionation,indications,recurrence patterns,local control and toxicities of SBRT in pancreatic tumors were included.All articles were assessed for validity and relevant content.Results:Optimal doses and fractionation have not yet been defined.However,SBRT could be the standard treatment in patients with pancreatic adenocarcinoma in addition to CRT.Furthermore,the combination of SBRT with chemotherapy may have additive or synergic effect on pancreatic adenocarcinoma.Conclusions:SBRT is an effective modality for patients with pancreatic cancer,supported by clinical practice guidelines as it has demonstrated good tolerance and good disease control.SBRT opens a possibility of improving outcomes for these patients,both in neoadjuvant treatment and with radical intent.

Diagnostic challenges and individualized treatment of cervical adenocarcinoma metastases to the breast:A case report

BACKGROUND Cervical cancer is a rare primary tumor resulting in metastases to the breast with few cases reported in literature.Breast metastases are associated with poor prognosis.The following case highlights the diagnostic challenges associated with metastatic cervical cancer to the breast along with individualized treatment.CASE SUMMARY A 44-year-old G7P5025 with no significant past medical or surgical history presented with heavy vaginal to an outside emergency department where an exam and a pelvic magnetic resonance imaging showed a 4.5 cm heterogenous lobulated cervical mass involving upper two thirds of vagina,parametria and lymph node metastases.Cervical biopsies confirmed high grade adenocarcinoma with mucinous features.A positron emission tomography/computed tomography(PET/CT)did not show evidence of metastatic disease.She received concurrent cisplatin with external beam radiation therapy.Follow up PET/CT scan three months later showed no suspicious fluorodeoxyglucose uptake in the cervix and no evidence of metastatic disease.Patient was lost to follow up for six months.She was re-imaged on re-presentation and found to have widely metastatic disease including breast disease.Breast biopsy confirmed programmed death-ligand 1 positive metastatic cervical cancer.The patient received six cycles of carboplatin and paclitaxel with pembrolizumab.Restaging imaging demonstrated response.Patient continued on pembrolizumab with disease control.CONCLUSION Metastatic cervical cancer to the breast is uncommon with nonspecific clinical findings that can make diagnosis challenging.Clinical history and immunohistochemical evaluation of breast lesion,and comparison to primary tumor can support diagnosis of metastatic cervical cancer to the breast.Overall,the prognosis is poor,but immunotherapy can be considered in select patients and may result in good disease response.

Early adenocarcinoma mixed with a neuroendocrine carcinoma component arising in the gastroesophageal junction: A case report

BACKGROUND Early adenocarcinoma mixed with a neuroendocrine carcinoma(NEC)component arising in the gastroesophageal junctional(GEJ)region is rare and even rarer in young patients.Here,we report such a case in a 29-year-old Chinese man.CASE SUMMARY This patient presented to our hospital with a 3-mo history of dysphagia and regurgitation.Upper endoscopy revealed an elevated nodule in the distal esophagus 1.6 cm above the GEJ line,without Barrett’s esophagus or involvement of the gastric cardia.The nodule was completely resected by endoscopic submu-cosal dissection(ESD).Pathological examination confirmed diagnosis of intra-mucosal adenocarcinoma mixed with an NEC component,measuring 1.5 cm.Immunohistochemically,both adenocarcinoma and NEC components were positive for P53 with a Ki67 index of 90%;NEC was positive for synaptophysin and chromogranin.Next-generation sequencing of 196 genes demonstrated a novel germline mutation of the ERCC3 gene in the DNA repair pathway and a germline mutation of the RNF43 gene,a common gastric cancer driver gene,in addition to pathogenic somatic mutations in P53 and CHEK2 genes.The patient was alive without evidence of the disease 36 mo after ESD.CONCLUSION Early adenocarcinoma with an NEC component arising in the distal esophageal side of the GEJ region showed evidence of gastric origin.

Clinical pathological characteristics of“crawling-type”gastric adenocarcinoma cancer:A case report

BACKGROUND Gastric cancer(GC)is a significant health problem worldwide,and early detection and accurate diagnosis are crucial for improving patient outcomes.Crawling-type gastric adenocarcinoma is a rare subtype of GC that has unique histopathological and clinical characteristics,and its diagnosis and management can be challenging.This pathological type of GC is also rare.CASE SUMMARY Here,we report the case of a patient who underwent ordinary endoscopy,na-rrow-band imaging,and endoscopic ultrasonography intending to determine the extent of tumor invasion and upper abdominal enhanced computed tomography and whether there was tumor metastasis.Then,endoscopic submucosal dissection was performed.After pathological and immunohistochemical examination,the pathological diagnosis was crawling-type gastric adenocarcinoma.This is a very rare and special pathological type of tumor.This case highlights the importance of using advanced endoscopic techniques and pathological examination in diagnosing and managing gastric crawling-type adenocarcinoma.Moreover,the findings underscore the need for continued research and clinical experience in this rare subtype of GC to improve patient outcomes.CONCLUSION The“crawling-type”GC is a rare and specific tumor pathology.It is difficult to identify and diagnose gliomas via endoscopy.The tumor is ill-defined,with a flat appearance and indistinct borders due to the lack of contrast against the background mucosa.Pathology revealed that the tumor cells were hand-like,so the patient has diagnosed with“crawling-type”gastric adenocarcinoma.

A 16-bit 18-MSPS flash-assisted SAR ADC with hybrid synchronous and asynchronous control logic

This paper presents a 16-bit,18-MSPS(million samples per second)flash-assisted successive-approximation-register(SAR)analog-to-digital converter(ADC)utilizing hybrid synchronous and asynchronous(HYSAS)timing control logic based on an on-chip delay-locked loop(DLL).The HYSAS scheme can provide a longer settling time for the capacitive digital-to-analog converter(CDAC)than the synchronous and asynchronous SAR ADC.Therefore,the issue of incomplete settling or ringing in the DAC voltage for cases of either on-chip or off-chip reference voltage can be solved to a large extent.In addition,the fore-ground calibration of the CDAC’s mismatch is performed with a finite-impulse-response bandpass filter(FIR-BPF)based least-mean-square(LMS)algorithm in an off-chip FPGA(field programmable gate array).Fabricated in 40-nm CMOS process,the proto-type ADC achieves 94.02-dB spurious-free dynamic range(SFDR),and 75.98-dB signal-to-noise-and-distortion ratio(SNDR)for a 2.88-MHz input under 18-MSPS sampling rate.

PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma:A case report

BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly fatal disease with limited effective treatment especially after first-line chemotherapy.The human epidermal growth factor receptor 2(HER-2)immunohistochemistry(IHC)positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC.CASE SUMMARY We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn’t have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment.A novel combination therapy PRaG 3.0 of RC48(HER2-antibody-drug conjugate),radio-therapy,PD-1 inhibitor,granulocyte-macrophage colony-stimulating factor and interleukin-2 was then applied as second-line therapy and the patient had confirmed good partial response with progress-free-survival of 6.5 months and overall survival of 14.2 month.She had not developed any grade 2 or above treatment-related adverse events at any point.Percentage of peripheral CD8^(+) Temra and CD4^(+) Temra were increased during first two activation cycles of PRaG 3.0 treatment containing radiotherapy but deceased to the baseline during the maintenance cycles containing no radiotherapy.CONCLUSION PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.

Radiotherapy for hyoid bone metastasis from lung adenocarcinoma:A case report

BACKGROUND Metastasis to the hyoid bone is an exceptionally rare occurrence,with documented cases limited to breast,liver,colon,skin,lung,and prostate cancers.This report highlights an unusual case involving the metastasis of lung adenocarcinoma to the hyoid bone,accompanied by a distinctive headache.Previous documentation involved surgical resection of the hyoid mass.We present a case displaying the benefits of palliative radiotherapy.CASE SUMMARY A 72-year-old non-smoking,non-alcoholic woman,initially under investigation for a year-long elevation in absolute lymphocyte count,presented with a monthlong history of intermittent throat pain.Despite negative findings in gastroenterological and otolaryngologic examinations,a contrast-enhanced chest computed tomography scan revealed a mediastinal mass and questionable soft tissue thickening in her left anterolateral neck.Subsequent imaging and biopsies confirmed the presence of lung adenocarcinoma metastasis to the hyoid bone.The patient was treated with platinum-based chemo-immunotherapy along with pembrolizumab.Ultimately,the lung cancer was unresponsive.Our patient opted for palliative radiation therapy instead of surgical resection to address her throat pain.As a result,her throat pain was alleviated,and it also incidentally resolved her chronic headaches.This is the second documented case of lung adenocarcinoma metastasizing to the hyoid bone.CONCLUSION Palliative radiotherapy may add to the quality of life in symptomatic patients with cancer metastatic to the hyoid bone.